Tema Etfs LLC Grows Stock Position in Nurix Therapeutics, Inc. $NRIX

Key Points

• Tema Etfs LLC significantly increased its stake in Nurix Therapeutics, up by 162.2% to own 59,146 shares valued at approximately $703,000.
• Insider selling occurred as Gwenn Hansen and CFO Houte Hans Van sold shares, with Hansen's sale decreasing their ownership by 5.87% and Van's by 13.20%.
• Nurix Therapeutics recently reported a revenue of $44.06 million for the quarter, significantly exceeding analyst estimates of $16.26 million, with an EPS of ($0.52), beating expectations.

Tema Etfs LLC boosted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 162.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,146 shares of the company's stock after buying an additional 36,589 shares during the period. Tema Etfs LLC owned 0.08% of Nurix Therapeutics worth $703,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in NRIX. Raymond James Financial Inc. acquired a new position in Nurix Therapeutics during the fourth quarter worth approximately $1,026,000. First Trust Advisors LP acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at approximately $2,560,000. Dimensional Fund Advisors LP increased its holdings in shares of Nurix Therapeutics by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 506,839 shares of the company's stock valued at $9,548,000 after purchasing an additional 5,270 shares during the period. MetLife Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 20.7% in the fourth quarter. MetLife Investment Management LLC now owns 42,539 shares of the company's stock valued at $801,000 after purchasing an additional 7,300 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Nurix Therapeutics by 422.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 14,885 shares of the company's stock valued at $280,000 after purchasing an additional 12,036 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 4,308 shares of the company's stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total value of $51,739.08. Following the sale, the insider directly owned 69,023 shares in the company, valued at $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 5,402 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the sale, the chief financial officer owned 35,512 shares in the company, valued at $391,697.36. This represents a 13.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,014 shares of company stock worth $163,014 over the last 90 days. Company insiders own 7.40% of the company's stock.

Analyst Ratings Changes

NRIX has been the topic of a number of recent analyst reports. Baird R W raised Nurix Therapeutics to a "strong-buy" rating in a report on Tuesday, August 26th. HC Wainwright dropped their price objective on Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, July 14th. Wall Street Zen raised Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Oppenheimer reaffirmed an "outperform" rating and set a $30.00 price objective (down previously from $32.00) on shares of Nurix Therapeutics in a report on Thursday, July 31st. Finally, Morgan Stanley set a $16.00 price objective on Nurix Therapeutics and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and an average price target of $28.87.

Nurix Therapeutics Price Performance

NRIX traded down $0.07 during trading on Friday, reaching $9.34. 1,832,002 shares of the stock were exchanged, compared to its average volume of 675,848. The business's 50 day moving average price is $11.20 and its two-hundred day moving average price is $11.73. The company has a market capitalization of $714.04 million, a price-to-earnings ratio of -3.58 and a beta of 2.10. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The company had revenue of $44.06 million for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. On average, analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.